Abstract
The exclusive position of scientific expertise in pharmaceutical regulation is being increasingly
challenged. Several authors suggest that lay knowledge could play a role in governing risks. We use
the literature to develop ideal-typical regulatory arrangements with low and high lay stakeholder
involvement: a technocratic and a democratic arrangement. We propose that a more
... read more